Nymox Pharma Files 6-K with Director Transaction Data
Ticker: NYMXF · Form: 6-K · Filed: Jan 2, 2025 · CIK: 1018735
| Field | Detail |
|---|---|
| Company | Nymox Pharmaceutical CORP (NYMXF) |
| Form Type | 6-K |
| Filed Date | Jan 2, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing-update, director-transactions, regulatory-filing
TL;DR
Nymox Pharma 6-K shows director activity for Q3 2024 and prior periods.
AI Summary
Nymox Pharmaceutical Corp. filed a 6-K report on January 2, 2025, detailing financial information for the period ending September 30, 2024. The filing includes data related to director memberships and transactions involving James G. Robinson during 2023 and 2024. Specific financial figures for the reported periods are not detailed in this summary.
Why It Matters
This filing provides transparency into the activities and potential insider transactions of Nymox Pharmaceutical's directors, which can influence investor perception and stock valuation.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) providing updated information, not a significant event like an acquisition or earnings miss.
Key Numbers
- 2024-09-30 — Reporting Period End Date (The filing covers financial information up to this date.)
- 2025-01-02 — Filing Date (The date the 6-K was submitted to the SEC.)
Key Players & Entities
- NYMOX PHARMACEUTICAL CORP (company) — Filer
- James G. Robinson (person) — Director Member with multiple transaction dates listed
FAQ
What specific financial results are reported for the period ending September 30, 2024?
The provided text does not contain specific financial results for the period ending September 30, 2024, but rather indicates it is the 'CONFORMED PERIOD OF REPORT'.
What type of transactions are detailed for James G. Robinson?
The filing lists multiple date ranges associated with 'nymox:JamesGRobinsonMember', suggesting director-related activities or transactions during those periods in 2023 and 2024.
What is the SIC code for Nymox Pharmaceutical Corp?
The Standard Industrial Classification (SIC) code for Nymox Pharmaceutical Corp. is 2835, which corresponds to 'IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES'.
What is the company's fiscal year end?
Nymox Pharmaceutical Corp.'s fiscal year ends on December 31 (1231).
What is the company's business address?
The business address is 9900 Cavendish Blvd., Suite 306, St. Laurent, Quebec, Canada, H4M 2V2.
Filing Stats: 174 words · 1 min read · ~1 pages · Grade level 14.4 · Accepted 2025-01-02 15:01:34
Filing Documents
- nymox_6k.htm (6-K) — 46KB
- nymox_ex991.htm (EX-99.1) — 469KB
- nymox_ex992.htm (EX-99.2) — 14KB
- nymox_ex991img1.jpg (GRAPHIC) — 4KB
- 0001640334-25-000006.txt ( ) — 2214KB
- nymox-20240930.xsd (EX-101.SCH) — 40KB
- nymox-20240930_lab.xml (EX-101.LAB) — 141KB
- nymox-20240930_cal.xml (EX-101.CAL) — 31KB
- nymox-20240930_pre.xml (EX-101.PRE) — 111KB
- nymox-20240930_def.xml (EX-101.DEF) — 50KB
- nymox_6k_htm.xml (XML) — 356KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NYMOX PHARMACEUTICAL CORPORATION (Registrant) By: /s/ Paul Averback, MD Paul Averback, MD President and Chief Executive Officer Date: January 02, 2025 3